Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1/2 6Phase 3 2Phase 1 2Phase 2/3 1

Status

Not yet recruiting 6Recruiting 5Withdrawn 3Active not recruiting 2Terminated 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1

Conditions

Pancreatic Neoplasms 3Colorectal Neoplasms 2Small Cell Lung Carcinoma 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9venetoclax 7toripalimab 7pembrolizumab 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7irinotecan sucrosofate 6Temozolomide 6Fluorouracil 6tislelizumab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5HMPL-013 5Etoposide 5Dexamethasone 5Cisplatin 5Carboplatin 5Capecitabine 5Biopsy 5sintilimab 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × irinotecan sucrosofate × Clear all
NCT06341309 2024-08-09

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

West China Hospital

Phase 1/2 Not yet recruiting
20 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06513455 2024-07-22

Irinotecan Liposome,Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer

Harbin Medical University

Phase 1/2 Not yet recruiting
132 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06434090 2024-05-30

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

Sun Yat-sen University

Phase 1/2 Not yet recruiting
74 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06370754 2024-04-17

FD-IMPACT

Fudan University

Phase 1/2 Not yet recruiting
117 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06332950 2024-03-27

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

Shanghai Chest Hospital

Phase 1/2 Not yet recruiting
80 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06259058 2024-03-15

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 1/2 Not yet recruiting
96 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔